Abstract
(1) Background: The aim of this dynamic-LC/MS-human-serum-proteomic-study was to identify potential proteins-candidates for biomarkers of acute ischemic stroke, their changes during acute phase of stroke and to define potential novel drug-targets. (2) Methods: A total of 32 patients (29–80 years) with acute ischemic stroke were enrolled to the study. The control group constituted 29 demographically-matched volunteers. Subjects with stroke presented clinical symptoms lasting no longer than 24 h, confirmed by neurological-examination and/or new cerebral ischemia visualized in the CT scans (computed tomography). The analysis of plasma proteome was performed using LC-MS (liquid chromatography–mass spectrometry). (3) Results: Ten proteins with significantly different serum concentrations between groups volunteers were: complement-factor-B, apolipoprotein-A-I, fibronectin, alpha-2-HS-glycoprotein, alpha-1B-glycoprotein, heat-shock-cognate-71kDa protein/heat-shock-related-70kDa-protein-2, thymidine phosphorylase-2, cytoplasmic-tryptophan-tRNA-ligase, ficolin-2, beta-Ala-His-dipeptidase. (4) Conclusions: This is the first dynamic LC-MS study performed on a clinical model which differentiates serum proteome of patients in acute phase of ischemic stroke in time series and compares to control group. Listed proteins should be considered as risk factors, markers of ischemic stroke or potential therapeutic targets. Further clinical validation might define their exact role in differential diagnostics, monitoring the course of the ischemic stroke or specifying them as novel drug targets.
Highlights
Stroke is among the most common causes of death and permanent disability in adults [1]
Basic biochemical test revealed the decreased level of potassium and high density lipoproteinin (HDL) in the stroke group when compared to controls
Füst et al [79] reported decreased levels of ficolin-2 on days 1 and 3 after stroke. Such results suggest that changes in ficolin-2 concentration would become a useful marker of the acute phase of ischemic stroke. This is the first dynamic Liquid Chromatography—Mass Spectrometry (LC-MS) study performed on a clinical model which differentiates serum proteome of patients in acute phase of ischemic stroke in time series and compares to control group
Summary
Stroke is among the most common causes of death and permanent disability in adults [1]. Eighty percent of strokes are caused by occlusion of the vessel lumen by thrombotic or embolic material [2]. Animal studies have shown that at the time of stroke the blood-brain barrier (BBB) is damaged and becomes permeable for greater amounts of proteins [3]. This mechanism may occur in humans [4]. Some reports suggest that the measurement of brain-derived proteins in plasma could be useful in diagnosis and monitoring acute phase of ischemic stroke [5]. Serum stroke biomarkers might be useful in risk stratification to determine the optimal way of treatment for specific patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
